Loading…
Loading…
EQUITY / NASDAQ · XNCM
Cellectar Biosciences, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗1.84 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.84 USD · Volume 74,870
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 33,993,982 USD | — | — |
| Net income | -6,930,653 USD | -5,447,911 USD | — |
| Operating profit | -7,196,012 USD | -6,037,529 USD | — |
| Total assets | 36,639,086 USD | — | — |
| Total equity | 29,871,833 USD | 6,085,012 USD | +390.91% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 33,993,982 USD | — | — | 13,196,033 USD | 13,196,033 USD | 12,554,289 USD | — | — |
| Net incomeIncome statement | -6,930,653 USD | -12,584,598 USD | -5,653,946 USD | — | -21,791,037 USD | -4,443,877 USD | -16,495,816 USD | -5,447,911 USD |
| Operating profitIncome statement | -7,196,012 USD | -12,989,953 USD | — | — | -22,979,844 USD | -4,850,696 USD | -17,289,215 USD | -6,037,529 USD |
| Total assetsBalance sheet | 36,639,086 USD | — | — | 14,978,321 USD | 14,978,321 USD | 14,627,590 USD | — | — |
| Total equityBalance sheet | 29,871,833 USD | — | 3,335,087 USD | 8,537,164 USD | 8,537,164 USD | 7,997,306 USD | — | 6,085,012 USD |
| Total liabilitiesBalance sheet | 6,767,253 USD | — | — | 5,059,134 USD | 5,059,134 USD | 5,248,261 USD | — | — |
| Capital expendituresCash flow statement | — | 3,378 USD | — | — | 5,880 USD | — | — | — |
| Financing cash flowCash flow statement | — | 31,657,069 USD | — | — | 13,031,523 USD | — | 8,039,763 USD | — |
| Investing cash flowCash flow statement | — | -3,378 USD | — | — | -5,880 USD | — | — | — |
| Operating cash flowCash flow statement | — | -10,855,742 USD | — | — | -23,118,217 USD | — | -18,774,081 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/04/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.